Journal decision profile

Clinical Pharmacology in Drug Development

Medicine · Pharmacology, Toxicology and Pharmaceutics

Clinical Pharmacology in Drug Development's 2026 Journal Metrics Score is 1.4, ranking Q2 in Pediatrics, Perinatology and Child Health. Two-year citation average from OpenAlex data, updated August 2026.

WileyUnited StatespISSN 2160-7648eISSN 2160-7648
Checking system sharing availability.Visit homepage

Bookmark this page — track observed submission-to-acceptance timing, FWCI and field-normalized citation data for this journal in one view.

Journal Metrics Score
i
Journal Metrics ScoreThe raw score is citations received in the latest complete year by works from the two previous years, divided by the number of those works. It is calculated from OpenAlex open data (CC0) and is not a percentage grade.
2026
1.4

Journal Metrics Score 2026 · 2021–2024 window citedness 1.61.

Review & acceptance time
i
Review & acceptance timeCalendar days between the received and accepted dates reported in recent PubMed records. This interval includes editorial handling and author revisions, so it is not time to first decision or pure peer-review time.
PUBMED
80 daysmedian

Middle 50%: 56–119 days

98 of 100 PubMed-indexed articles · 98% coverage · 2024–2025

Clinical Pharmacology in Drug Development accepts papers a median of 80 days after submission, including peer review and revisions. That is faster than 84% of comparable journals with PubMed timing data.

Indicative APC
i
Indicative APCThis journal-level estimate comes from the OpenAlex source record. It is not a verified quote and may exclude taxes, waivers, society discounts, or article-type charges. Check the journal's official website before deciding.
OPENALEX · VERIFY
$3,800

Journal-level estimate only. Verify current charges, taxes, waivers, discounts, and article-type fees with the journal.

Free preview · no sign-in

Does your manuscript fit Clinical Pharmacology in Drug Development?

Paste your title to see which of this journal's published topics it overlaps with. Your title stays in your browser for this preview and is not sent anywhere.

Want ranked journals with fit reasons, risks and a submission strategy instead? See a sample AI report.

At a glance

Journal decision profile

Each spoke is a 0–100 percentile within a comparable journal cohort—not a percentage grade or a single black-box rating.

Relative profile

Metrics ScoreThe raw 2026 Journal Metrics Score is the recent two-year citation average shown above. The radar converts it to a 0–100 cohort percentile: farther out means a higher score than more comparable journals. It is not a percentage grade.iSource outputThe raw rank compares lifetime output inside the journal’s leading-topic source set. The radar then compares that rank position across Decision Profile journals in the same primary OpenAlex field; when that field has too few profiles, it uses the broader profile set. Farther out means relatively more output, not better research quality.iTop 10% shareThe share of recent papers in the global top 10% for citations after comparing papers of the same type, publication year, and subfield. The radar converts that share to a 0–100 cohort percentile; it does not predict how a new paper will perform.iMedian FWCICitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected citation level for comparable papers; the radar shows its 0–100 cohort percentile.iSubmission-to-acceptanceCalendar days from the received date to the accepted date in recent PubMed records. This includes editorial handling and author revisions, so it is not the time to first decision and not pure peer-review time. The radar uses a 0–100 cohort percentile with shorter observed timing plotted farther out; it does not measure review quality.iOutput volumeAverage works published per year in the recent analysis window, converted to a 0–100 cohort percentile. Farther out means the journal publishes more papers; it does not mean those papers are better.i
Cost is intentionally excluded. Missing APC data is never converted to a zero-dollar fee or a fabricated cost score.

Raw values behind the shape

Always visible
Metrics Score
i
Metrics ScoreThe 2026 raw Journal Metrics Score shown above. The bar is its 0–100 percentile within the radar's comparable journal cohort; it is not a percentage score.
1.42026 · OPENALEX
Source output rank
i
Source output rankThis lifetime journal-wide output rank compares works published by the OpenAlex source with sources associated with the journal’s leading topic. More output does not mean higher quality.
#341 / 1,660LIFETIME OUTPUT
Highly cited papers
i
Highly cited papersShare of recent works in the global top 10% for citations after comparing papers of the same type, publication year, and subfield.
6.1%FIELD-NORMALIZED TOP 10%
Field-normalized impact
i
Field-normalized impactCitation performance of the middle recent paper after field, year, and work type are considered. A raw FWCI of 1.0 is the expected level for comparable work.
0.68MEDIAN FWCI
Submission-to-acceptance
i
Submission-to-acceptanceReceived-to-accepted calendar days from qualified PubMed records. It includes editorial handling and author revisions; it is not time to first decision or pure peer-review time.
80 daysIQR 56–119 DAYS
Recent output
i
Recent outputAverage works published per year across the complete analysis window. This is a volume measure, not a quality score.
161 / yr2021–2024 AVG
Field-normalized top 10% share6.1%

39 of 642 works · same type, year & subfield

Field-normalized top 1% share0%

0 works · same type, year & subfield

Median FWCI0.68×

Below field-year expectation

Source output rank#341

of 1,660 topic-associated OpenAlex sources by lifetime output

What does Median FWCI mean?

FWCI compares papers with the same publication year, type, and field. 1.0 is the world average; above 1.0 is above expectation. This journal's median is 0.68, so its typical recent paper runs about 32% below its field benchmark.

What does Top 10% Share mean?

6.1% of recent papers rank in the global top 10% after field normalization. This is easier to compare across specialties than raw citation totals.

Publishing pattern

Publication volume and article mix

Volume is separated from citation accumulation so newer papers are not presented as weaker simply because they are newer.

Works published by year

OpenAlex source records · 2016–2025

742016
1132017
1242018
1172019
1292020
1632021
1742022
1512023
1542024
1532025

Recent work-type mix

642 OpenAlex works · 2021–2024

Article82.7%
Paratext16.4%
Other0.3%
Conference abstract0.2%
Editorial0.2%
Erratum0.2%
OpenAlex article is broader than “original research.” PubMed Publication Types can add case-report and clinical-study detail.
Fit signals

Topics and medical subject coverage

OpenAlex topics show research communities; MeSH keeps the medical taxonomy recognizable.

Major MeSH signals

PubMed-indexed works

Select a MeSH signal to see how much Clinical Pharmacology in Drug Development publishes on it, from PubMed counts for the last five complete years.

Leading OpenAlex topics

2021–2024 works
Pharmacogenetics and Drug Metabolism115
Pharmaceutical studies and practices32
Statistical Methods in Clinical Trials29
Biosimilars and Bioanalytical Methods27
Cardiac electrophysiology and arrhythmias26
Diabetes Treatment and Management17
Antibiotics Pharmacokinetics and Efficacy13
Migraine and Headache Studies12
HIV/AIDS drug development and treatment9
Erythropoietin and Anemia Treatment8
Methodology: OpenAlex snapshot 2026-10-23. FWCI, percentile badges, topics, and type mix use 642 works published 2021–2024. Radar normalization is versioned in the cached profile, and no cost score is assigned without reliable APC data.

Subject Category Quartiles

Quartiles computed within each OpenAlex subfield
CategoryQuartile
Pediatrics, Perinatology and Child HealthQ2
PharmacologyQ3
Endocrinology, Diabetes and MetabolismQ3
OncologyQ3
Q2
Subfield Quartile
B4
CAS Block

Ranking and source check

#3,580
of 6,272 Medicine field journals
#1,317
among Q2 Medicine journals

Confirm the exact title and ISSNs against the publisher homepage before a high-stakes submission decision.

Journal Details

OpenAlex Works
1,732
H-Index
46
Fully Open Access
No
Recent OA Works
843
Subject Areas
Pediatrics, Perinatology and Child HealthPharmacologyEndocrinology, Diabetes and MetabolismOncology

Source: the current OpenAlex source record. OpenAlex works can include multiple work types. Fully Open Access is a source-level flag. Recent OA Works is summed from OpenAlex's counts_by_year series (up to the latest ten years); it is not a lifetime OA percentage. Any APC shown here is an indicative OpenAlex value—verify current charges on the journal's official website.

Common questions about Clinical Pharmacology in Drug Development

What is Clinical Pharmacology in Drug Development's Journal Metrics Score in 2026?

Clinical Pharmacology in Drug Development's 2026 Journal Metrics Score is 1.4, from the August 2026 data release. The score is a two-year citation average computed from OpenAlex (CC0) data: citations received in the most recent complete year to works published in the two prior years, divided by the number of those works.

What quartile is Clinical Pharmacology in Drug Development in?

Clinical Pharmacology in Drug Development's best quartile is Q2. By OpenAlex subfield: Q2 in Pediatrics, Perinatology and Child Health; Q3 in Pharmacology; Q3 in Endocrinology, Diabetes and Metabolism; Q3 in Oncology. Quartiles rank journals by Journal Metrics Score within each subfield.

Is the Journal Metrics Score the same as other journal citation metrics?

No. Journal Metrics computes the score independently from OpenAlex open data. Other providers use different citation databases, document types, and counting rules, so their published figures for Clinical Pharmacology in Drug Development will not match this score exactly. Compare journals using one source at a time.

How long does Clinical Pharmacology in Drug Development take to accept a paper?

Clinical Pharmacology in Drug Development accepts papers a median of 80 days after submission across 98 recent PubMed records with both dates; the middle half took 56–119 days. This includes peer review, editorial handling, and revisions.

How long is the peer review time at Clinical Pharmacology in Drug Development?

PubMed records when a manuscript was received and accepted, not the individual review stages, so peer review time on its own is not available. The full time from submission to acceptance at Clinical Pharmacology in Drug Development, which includes peer review and revisions, has a median of 80 days. For the time to a first decision, check the journal's own website.

Is Clinical Pharmacology in Drug Development faster than similar journals?

Clinical Pharmacology in Drug Development's median of 80 days from submission to acceptance is faster than 84% of comparable journals with PubMed timing data.

How much does it cost to publish in Clinical Pharmacology in Drug Development?

OpenAlex lists an indicative article processing charge of $3,800 USD for Clinical Pharmacology in Drug Development. This journal-level estimate may exclude taxes, waivers, discounts, or article-type fees, so confirm the current charge on the journal's website.

Which journals are alternatives to Clinical Pharmacology in Drug Development?

Comparable journals include Expert Opinion On Drug Metabolism & Toxicology, Clinical Pharmacology & Therapeutics, European Journal of Drug Metabolism and Pharmacokinetics, and Clinical Pharmacokinetics. Compare their scores, acceptance times, and costs in the recommended alternatives on this page before choosing where to submit.

Cite an article from this journal
Back to Search